Top

23-07-2018 | Osteoporosis | Article

Incidence, risk factors, and fracture healing of atypical femoral fractures: a multicenter case-control study

Journal: Osteoporosis International

Authors: S.-J. Lim, I. Yeo, P.-W. Yoon, J.J. Yoo, K.-H. Rhyu, S.-B. Han, W.-S. Lee, J.-H. Song, B.-W. Min, Y.-S. Park

Publisher: Springer London

Abstract

Summary

The incidence of atypical femoral fractures (AFFs) was 2.95% among 6644 hip and femoral fractures. Independent risk factors included the use of bisphosphonates (BPs), osteopenia or osteoporosis, rheumatoid arthritis, increased femoral curvatures, and thicker femoral cortices. Patients with AFFs and BP treatment were more likely to have problematic healing than those with typical femoral fractures (TFFs) and no BP treatment.

Introduction

To determine the incidence and risk factors of atypical femoral fractures (AFFs), we performed a multicenter case-control study. We also investigated the effects of bisphosphonates (BPs) on AFF healing.

Methods

We retrospectively reviewed the medical records and radiographs of 6644 hip and femoral fractures of patients from eight tertiary referral hospitals. All the radiographs were reviewed to distinguish AFFs from TFFs. Univariate and multivariate logistic regression analyses were performed to identify risk factors, and interaction analyses were used to investigate the effects of BPs on fracture healing.

Results

The incidence of AFFs among 6644 hip and femoral fractures was 2.95% (90 subtrochanter and 106 femoral shaft fractures). All patients were females with a mean age of 72 years, and 75.5% were exposed to BPs for an average duration of 5.2 years (range, 1–17 years). The use of BPs was significantly associated with AFFs (p < 0.001, odds ratio = 25.65; 95% confidence interval = 10.74–61.28). Other independent risk factors for AFFs included osteopenia or osteoporosis, rheumatoid arthritis, increased anterior and lateral femoral curvatures, and thicker lateral femoral cortex at the shaft level. Interaction analyses showed that patients with AFFs using BPs had a significantly higher risk of problematic fracture healing than those with TFFs and no BP treatment.

Conclusions

The incidence of AFFs among 6644 hip and femoral fractures was 2.95%. Osteopenia or osteoporosis, use of BPs, rheumatoid arthritis, increased anterior and lateral femoral curvatures, and thicker lateral femoral cortex were independent risk factors for the development of AFFs. Patients with AFFs and BP treatment were more likely to have problematic fracture healing than those with TFFs and no BP treatment.

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19(6):733–759CrossRef

Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster DW, Ebeling PR, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O’Keefe R, Papapoulos S, Howe TS, van der Meulen MC, Weinstein RS, Whyte MP (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1–23CrossRef

Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90(3):1294–1301CrossRef

Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305(8):783–789CrossRef

Rizzoli R, Akesson K, Bouxsein M, Kanis JA, Napoli N, Papapoulos S, Reginster JY, Cooper C (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation working group report. Osteoporos Int 22(2):373–790CrossRef

Kim SM, Park YS, Moon YW, Kang SH, Yeo I, Oh SM, Lim SJ (2016) Atypical complete femoral fractures associated with bisphosphonate use or not associated with bisphosphonate use: is there a difference? Biomed Res Int 2016:4753170, 1, 8

Lo JC, Hui RL, Grimsrud CD, Chandra M, Neugebauer RS, Gonzalez JR, Budayr A, Lau G, Ettinger B (2016) The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy. Bone 85:142–147CrossRef

Kim SC, Kim DH, Mogun H, Eddings W, Polinski JM, Franklin JM, Solomon DH (2016) Impact of the US Food and Drug Administration’s safety-related announcements on the use of bisphosphonates after hip fracture. J Bone Miner Res 31(8):1536–1540CrossRef

Koh JH, Myong JP, Yoo J, Lim YW, Lee J, Kwok SK, Park SH, Ju JH (2017) Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years’ experience in a single center. Osteoporos Int 28(11):3251–3259CrossRef

10.

Kim JW, Kim JJ, Byun YS, Shon OJ, Oh HK, Park KC, Kim JW, Oh CW (2017) Factors affecting fracture location in atypical femoral fractures: a cross-sectional study with 147 patients. Injury 48(7):1570–1574CrossRef

11.

Lee YK, Kim TY, Ha YC, Song SH, Kim JW, Shon HC, Chang JS, Koo KH (2017) Atypical subtrochanteric fractures in Korean hip fracture study. Osteoporos Int 28(10):2853–2858CrossRef

12.

Kharwadkar N, Mayne B, Lawrence JE, Khanduja V (2017) Bisphosphonates and atypical subtrochanteric fractures of the femur. Bone Joint Res 6(3):144–153CrossRef

13.

Lloyd AA, Gludovatz B, Riedel C, Luengo EA, Saiyed R, Marty E, Lorich DG, Lane JM, Ritchie RO, Busse B, Donnelly E (2017) Atypical fracture with long-term bisphosphonate therapy is associated with altered cortical composition and reduced fracture resistance. Proc Natl Acad Sci U S A 114(33):8722–8727CrossRef

14.

Chen LP, Chang TK, Huang TY, Kwok TG, Lu YC (2014) The correlation between lateral bowing angle of the femur and the location of atypical femur fractures. Calcif Tissue Int 95(3):240–247CrossRef

15.

Saita Y, Ishijima M, Mogami A, Kubota M, Baba T, Kaketa T, Nagao M, Sakamoto Y, Sakai K, Kato R, Nagura N, Miyagawa K, Wada T, Liu L, Obayashi O, Shitoto K, Nozawa M, Kajihara H, Gen H, Kaneko K (2014) The fracture sites of atypical femoral fractures are associated with the weight-bearing lower limb alignment. Bone 66:105–110CrossRef

16.

Hyodo K, Nishino T, Kamada H, Nozawa D, Mishima H, Yamazaki M (2017) Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases. J Bone Miner Metab 35(2):209–214CrossRef

17.

Koh A, Guerado E, Giannoudis PV (2017) Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management. Bone Joint J 99-B(3):295–302CrossRef

18.

Weil YA, Rivkin G, Safran O, Liebergall M, Foldes AJ (2011) The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma 71(1):186–190CrossRef

19.

Egol KA, Park JH, Rosenberg ZS, Peck V, Tejwani NC (2014) Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res 472(9):2728–2734CrossRef

20.

Kang JS, Won YY, Kim JO, Min BW, Lee KH, Park KK, Song JH, Kim YT, Kim GH (2014) Atypical femoral fractures after anti-osteoporotic medication: a Korean multicenter study. Int Orthop 38(6):1247–1253CrossRef

21.

Lim HS, Kim CK, Park YS, Moon YW, Lim SJ, Kim SM (2016) Factors associated with increased healing time in complete femoral fractures after long-term bisphosphonate therapy. J Bone Joint Surg Am 98(23):1978–1987CrossRef

22.

Cho JW, Oh CW, Leung F, Park KC, Wong MK, Kwek E, Kim HJ, Oh JK (2017) Healing of atypical subtrochanteric femur fractures after cephalomedullary nailing: which factors predict union? J Orthop Trauma 31(3):138–145CrossRef

23.

Adams AL, Xue F, Chantra JQ, Dell RM, Ott SM, Silverman S, Giaconi JC, Critchlow C (2017) Sensitivity and specificity of radiographic characteristics in atypical femoral fractures. Osteoporos Int 28(1):413–417CrossRef

24.

Park HA, Park JK, Park SA, Lee JS (2010) Age, menopause, and cardiovascular risk factors among Korean middle-aged women: the 2005 Korea National Health and nutrition examination survey. J Women's Health (Larchmt) 19(5):869–876CrossRef

25.

Kim BJ, Lee SH, Koh JM, Kim GS (2013) The association between higher serum ferritin level and lower bone mineral density is prominent in women ≥ 45 years of age (KNHANES 2008–2010). Osteoporos Int 24(10):2627–2637CrossRef

26.

Lo JC, Zheng P, Grimsrud CD, Chandra M, Ettinger B, Budayr A, Lau G, Baur MM, Hui RL, Neugebauer R (2014) Racial/ethnic differences in hip and diaphyseal femur fractures. Osteoporos Int 25(9):2313–2318CrossRef

27.

Kanis JA, Harvey NC, Cooper C, Johansson H, Odén A, McCloskey EV; Advisory Board of the National Osteoporosis Guideline Group. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos (1):25

28.

Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9(8):1137–1141CrossRef

29.

Whelan DB, Bhandari M, McKee MD, Guyatt GH, Kreder HJ, Stephen D, Schemitsch EH (2002) Interobserver and intraobserver variation in the assessment of the healing of tibial fractures after intramedullary fixation. J Bone Joint Surg Br 84(1):15–18CrossRef

30.

Koeppen VA, Schilcher J, Aspenberg P (2012) Atypical fractures do not have a thicker cortex. Osteoporos Int 23(12):2893–2896CrossRef

31.

Napoli N, Jin J, Peters K, Wustrack R, Burch S, Chau A, Cauley J, Ensrud K, Kelly M, Black DM (2012) Are women with thicker cortices in the femoral shaft at higher risk of subtrochanteric/diaphyseal fractures? The study of osteoporotic fractures. J Clin Endocrinol Metab 97(7):2414–2422CrossRef

32.

Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85(1):37–44CrossRef

33.

Donnelly E, Meredith DS, Nguyen JT, Gladnick BP, Rebolledo BJ, Shaffer AD, Lorich DG, Lane JM, Boskey AL (2012) Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 27(3):672–678CrossRef

34.

Lee SH, Lee YH, Suh JS (2017) Lateral cortical thickening and bone heterogeneity of the subtrochanteric femur measured with quantitative CT as indicators for early detection of atypical femoral fractures in long-term bisphosphonate users. AJR Am J Roentgenol 209(4):867–873CrossRef

35.

Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, Compston JE, Drake MT, Edwards BJ, Favus MJ, Greenspan SL, McKinney R Jr, Pignolo RJ, Sellmeyer DE (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 31(1):16–35CrossRef

36.

Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal osteoporosis. N Engl J Med 374(3):254–262CrossRef

37.

Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP (2017) Osteoporosis in crisis: it’s time to focus on fracture. J Bone Miner Res 32(7):1391–1394CrossRef

38.

Saita Y, Ishijima M, Mogami A, Kubota M, Baba T, Kaketa T, Nagao M, Sakamoto Y, Sakai K, Homma Y, Kato R, Nagura N, Miyagawa K, Wada T, Liu L, Matsuoka J, Obayashi O, Shitoto K, Nozawa M, Kajihara H, Gen H, Kaneko K (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab (3, 3):311–318CrossRef

39.

Beaudouin-Bazire C, Dalmas N, Bourgeois J, Babinet A, Anract P, Chantelot C, Farizon F, Chopin F, Briot K, Roux C, Cortet B, Thomas T (2013) Real frequency of ordinary and atypical sub-trochanteric and diaphyseal fractures in France based on X-rays and medical file analysis. Joint Bone Spine 80(2):201–205CrossRef

40.

Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728–1737CrossRef

41.

Thompson RN, Phillips JR, McCauley SH, Elliott JR, Moran CG (2012) Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 94(3:385–390CrossRef